FDA Grants Hemispherx Biopharma Extension (HEB)

by Benzinga Staff

December 14, 2010 10:07 AM | 10 seconds read | Make a Comment

FDA Grants Hemispherx Biopharma

HEB

Extension In Its Pending NDA For Treatment Of Chronic Fatigue Syndrome. At last check the stock was up 6% from yesterday's close at $0.535.

Posted In: FDA Biotechnology Health Care

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.